ENZON PHARMACEUTICALS, INC. 8-K

What Happened

• Enzon Pharmaceuticals, Inc. announced on March 10, 2026 that it entered into the Ninth Amendment to its Section 382 Rights Agreement (originally dated August 14, 2020) to move the Final Expiration Date of the rights to noon, New York City time, on March 18, 2026. The Rights Agreement otherwise remains unchanged.
• In a related disclosure (press release dated March 11, 2026), Enzon said it extended the expiration for its exchange offer to convert Series C Non‑Convertible Redeemable Preferred Stock into common stock; after the extension the Offer now expires at 5:00 p.m. Eastern time on March 16, 2026, unless further extended. The company is pursuing a proposed transaction with Viskase and has filed a Form S-4 registration statement related to that transaction.

Key Details

• Ninth Amendment executed March 10, 2026; new Rights Agreement Final Expiration: noon (NYC) March 18, 2026.
• Exchange offer (Series C preferred → common stock) extended by press release on March 11, 2026 to 5:00 p.m. ET on March 16, 2026.
• Rights agent: Continental Stock Transfer & Trust Company; the Rights Agreement was originally adopted Aug 14, 2020 and has been extended multiple times through prior amendments.
• Enzon and Viskase filed a Registration Statement on Form S-4 (includes prospectus/consent solicitation/offer to exchange) for the proposed merger/transactions.

Why It Matters

• The Ninth Amendment preserves the rights schedule and extends the time window for actions tied to those rights; this affects the timeline for stockholder decisions and any ownership-change protections under the Section 382 framework.
• The exchange offer extension gives holders of Series C Preferred more time to decide whether to convert into common stock, which can affect share count and investor position ahead of the proposed merger with Viskase.
• Investors should review the registration statement on Form S-4 and the company’s press release for full details and note the updated deadlines. The filing also contains standard forward‑looking risk disclosures about the proposed transaction.